Search results for: 'china cell and gene therapy industry development waste ppe'

In recent years, single-cell analysis has changed rapidly. It began as a niche, specialized technology with few companies offering solutions, which then became commonly used in academia. Subsequently, its use has spread to areas such as biopharma, with more companies investing in the research and development (R&D) of single-cell analysis projects. ...

This research service on the global cell banking market addresses market sizing, emerging trends, and technologies and provides a snapshot of the key participants in the market. The base year considered is 2015 and forecasts are provided from 2016 to 2020. The cell banking market is expected to grow at a CAGR of 16.7% till 2020, driven by special...

19 Jan 2018  |  North America  |  Market Research

The Global Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022

The Next Generation of Cancer Therapies

Infographics

×

Key Issues Addressed

Immuno-oncology refers to drugs that are used to stimulate the human immune system to target the fight against cancer. The immune system is capable of recognizing and eliminating foreign substances, including tumor cells. Tumors have, however, been able to escape detection by the immune system. There are drugs that can empower the immune system cel...

24 Jul 2020  |  North America  |  Market Research

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

Infographics

×

Key Issues Addressed

With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping therapeutics, diagnostics, and drug delivery across infectious diseases, oncology, rare genetic disorders, autoimmune conditions, cardiovascular disease, pulmonary fibrosis, neurodegeneratio...

COVID-19 has accelerated the need for a faster, more accessible clinical trial process. During the height of the pandemic, in-person follow-ups for ongoing trials were replaced with hand-held devices that essentially built an ecosystem for home health care support services that can be easily leveraged to avoid or reduce participant dropout rates. ...

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...